What is Suda?
Suda is a biotechnology firm dedicated to pioneering novel treatments for cancer, focusing on an anagrelide-based therapy. Beyond its oncology initiatives, the company is also advancing ZolpiMist, a short-term insomnia treatment, awaiting regulatory feedback from its TGA submission. Suda is also engaged in collaborative product development with several established partners, including Sanofi, Strides Pharma Global, Laboratorios Ordesa, Zelira Therapeutics, and Cann Pharmaceutical Australia, indicating a broad strategic approach to drug development and commercialization.
How much funding has Suda raised?
Suda has raised a total of $2.7M across 1 funding round:
Share Placement
$2.7M
Share Placement (2020): $2.7M, investors not publicly disclosed
What's next for Suda?
The substantial enterprise-level funding context suggests Suda is in a critical growth phase, likely focused on scaling its operations and advancing its lead cancer therapeutic through clinical trials. The recent strategic investment signals strong investor confidence in Suda's innovative approach and its potential to address significant unmet medical needs. Future developments will likely involve progress in its oncology pipeline and potential commercialization milestones for ZolpiMist, supported by its strategic partnerships.
See full Suda company page
